ReviewClinical reviews in allergy & immunology2025
Malignancy in Idiopathic Inflammatory Myopathies: Recent Insights.
Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Paraneoplastic Myopathy as a Possible Initial Presentation of Sporadic Burkitt Lymphoma in an Immunocompetent Adult: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Mental- and physical-health comorbidity are strongly associated in idiopathic inflammatory myopathies: a multinational cross-sectional e-survey.Rheumatology international · 2026Article
- Dysregulation of the cytotoxic-humoral axis and expansion of regulatory T cells in anti-TIF1γ- positive dermatomyositis.Frontiers in immunology · 2026Article
- Immune Myositis Complicating Follicular Lymphoma: Case Report.Reports (MDPI) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Idiopathic inflammatory myopathies (IIMs) are a group of rare autoimmune diseases in which several subtypes, primarily dermatomyositis (DM), are associated with a high risk of malignancy. Although the relationship between the pathogenesis of IIMs and co-occurring malignancy is poorly understood, there is a growing evidence base for specific risk factors which are associated with cancer-associated myositis (CAM), including myositis-specific or myositis-associated autoantibodies (MSAs/MAAs). In addition, given that patients with different subtypes of IIMs, as classified according to clinical manifestations or serum autoantibody measurement, exhibit heterogeneity in tumorigenesis, further research is urgently needed to explore the pathogenesis of CAM, in order to develop novel biomarkers and therapeutic alternatives for patients. This review discusses the risk and protective factors for CAM using the available evidence, thereby offering fresh insights into its pathogenesis, screening, and management strategies and highlighting possible future breakthroughs and obstacles in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.